The use of oral methotrexate (mtx) in the treatment of tumours in the head and neck-region.
D000230:Adenocarcinoma / Q000188:drug therapy / Q000532:radiotherapy; D000284:Administration, Oral; D000368:Aged; D003528:Carcinoma, Adenoid Cystic / Q000188:drug therapy / Q000532:radiotherapy; D002280:Basal Cell Carcinoma / Q000188:drug therapy / Q000532:radiotherapy; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy / Q000532:radiotherapy; D003537:Cystadenoma / Q000188:drug therapy / Q000532:radiotherapy; D004428:Ear Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000532:radiotherapy; D005260:Female; D006367:HeLa Cells; D006257:Head; D006258:Head and Neck Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000532:radiotherapy; D006801:Humans; D002955:Leucovorin; D016403:Lymphoma, Large B-Cell, Diffuse / Q000188:drug therapy / Q000532:radiotherapy; D008297:Male; D008727:Methotrexate / Q000008:administration & dosage* / Q000494:pharmacology; D008875:Middle Aged; D009062:Mouth Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000532:radiotherapy; D012516:Osteosarcoma / Q000188:drug therapy / Q000532:radiotherapy
D002955:Leucovorin; D008727:Methotrexate